Statement
20 Nov 2025
WIPO Committee on IP and Development (CDIP 35): Technology Transfer
On 20 November 2025, IFPMA submitted a statement on technology transfer at the WIPO Committee on IP and Development (CDIP 35) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which...
Read more
Statement
5 Nov 2025
WIPO Standing Committee on Patents (SCP 37): Technology Transfer
On 5 November 2025, IFPMA delivered a statement on technology transfer at the WIPO Standing Committee on Patents (SCP 37) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which is...
Read more
Statement
4 Nov 2025
WIPO Standing Committee on Patents (SCP 37): Patents and health
On 4 November 2025, IFPMA delivered a statement on patents and health at the WIPO Standing Committee on Patents (SCP 37) in Geneva. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global research-based biopharmaceutical industry. We appreciate the opportunity to address the Committee on patents and health. Intellectual property is fundamental to...
Read more
